22:06 , Jun 14, 2018 |  BC Innovations  |  Translation in Brief

There’s more to MIF

In a May Science Translational Medicine study, a European-U.S. team has shown macrophage migration inhibitory factor or sCD74, a soluble form of one its receptors, could reduce the risk of acute kidney injury in cardiac...
18:26 , Jun 13, 2018 |  BC Innovations  |  Distillery Techniques

Assays and screens

TECHNOLOGY: Diagnostic assays A microfluidics-based method for detecting tumor cells in urine could help diagnose bladder cancer. The assay involves two steps: adding patient urine samples to a microfluidics device consisting of a chamber for directional...
16:58 , Feb 13, 2018 |  BC Innovations  |  Distillery Techniques

Assays and screens; disease models

TECHNOLOGY: Cellular assays; 3-D models A 3-D culture system that mimics brain tissue could be used to model drug resistance in glioblastoma multiforme and screen therapies. The system involves culturing human GBM cell lines in a...
01:09 , Dec 13, 2017 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Pancreatic cancer Patient sample and cell culture studies suggest inhibiting KMT5C could help treat pancreatic cancer. In tumor samples from pancreatic cancer patients, KMT5C expression was higher in invasive tumors than in adjacent normal pancreatic...
14:02 , Dec 11, 2017 |  BC Extra  |  Preclinical News

Histone modifier is implicated in epithelial-mesenchymal transition

In a paper published in the Journal of Cell Biology, researchers at the Genentech Inc. unit of Roche (SIX:ROG; OTCQX:RHHBY) identified a histone modifier that may regulate epithelial-mesenchymal transition (EMT), a process associated with tumor...
17:50 , Nov 2, 2017 |  BC Innovations  |  Product R&D

Sweet specificity

Siamab Therapeutics Inc. is gearing up to compete in the small but active space of companies targeting sugar groups that are up-regulated in cancer. So far, its technology has produced a lead therapeutic, a deal...
23:07 , Nov 2, 2016 |  BC Week In Review  |  Clinical News

AMC303: Ph I/Ib started

amcure began an open-label, dose-escalation, dose-expansion, European Phase I/Ib trial to evaluate AMC303 in up to 50 patients. amcure GmbH, Eggenstein-Leopoldshafen, Germany  Product: AMC303  Business: Cancer  Molecular target: Splice variant v6 of CD44 (CD44v6)  Description: Peptide inhibitor of CDD44v6  Indication: Treat...
07:00 , May 18, 2015 |  BC Week In Review  |  Company News

San Raffaele, MolMed deal

MolMed exercised an option to purchase a chimeric antigen receptor (CAR)- splice variant v6 of CD44 (CD44v6) from San Raffaele. MolMed said the compound has applications in hematological and solid tumors. The companies could not...
07:00 , Jul 28, 2014 |  BioCentury  |  Emerging Company Profile

amcure: Reimagining angiogenesis

amcure GmbH is developing peptide-based inhibitors of CD44v6, a tumor-specific co-receptor of tyrosine kinases including VEGFR-2 and c-Met. The approach could allow for higher dosing with fewer side effects than direct-acting tyrosine kinase inhibitors, while...
07:00 , Apr 17, 2014 |  BC Innovations  |  Targets & Mechanisms

Unfolding triple-negative breast cancer

A team from Weill Cornell Medical College has found a unifying feature of triple-negative breast cancers-overactivation of the transcription factor X-box binding protein 1-that could open the door to new therapies for this notoriously hard-to-treat...